Geode Capital Management LLC Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Geode Capital Management LLC boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 5.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 765,436 shares of the company's stock after purchasing an additional 39,815 shares during the period. Geode Capital Management LLC owned approximately 1.89% of Keros Therapeutics worth $12,120,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC raised its stake in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics during the fourth quarter worth $90,000. Exchange Traded Concepts LLC purchased a new position in Keros Therapeutics in the fourth quarter worth $99,000. China Universal Asset Management Co. Ltd. lifted its holdings in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after acquiring an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 22.90% of the stock is owned by company insiders.

Keros Therapeutics Price Performance

NASDAQ:KROS traded down $0.21 on Friday, reaching $14.21. The stock had a trading volume of 1,003,205 shares, compared to its average volume of 799,227. The company has a market cap of $576.39 million, a price-to-earnings ratio of -2.73 and a beta of 1.39. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The firm's fifty day moving average is $11.56 and its two-hundred day moving average is $27.87.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on KROS shares. Wedbush reiterated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Scotiabank reduced their price objective on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. Finally, Cantor Fitzgerald lowered Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.